Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02552147 · ClinicalTrials.gov registry record · Phase 1
Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02552147 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 8 participants.
The verdict
NCT02552147, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Some individuals with autism spectrum disorders (ASD) also demonstrate irritability or aggression, which can interfere with functioning. The purpose of this pilot study is to test whether transdermal nicotine is effective for irritability and/or aggression in adults with ASD using a double-blind, placebo-controlled clinical trial. Subjects will participate in three visits. At the first visit, subjects are screened for eligibility and enrolled. Baseline measures include rating scales and a frustrative computerized task. They will then wear seven days of transdermal nicotine or placebo. Visit two is on day seven and the study measures are repeated, vital signs and side effects monitored. Subjects will return for a third and final visit on day 21 to repeat the study measures performed during visit two.
Interventions
- DRUG Transdermal nicotine
- OTHER Transdermal placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02552147
The ClinicalTrials.gov registry entry for NCT02552147 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transdermal nicotine is the first listed.
NCT02552147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02552147 about?
NCT02552147 is a clinical study titled "Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism". Some individuals with autism spectrum disorders (ASD) also demonstrate irritability or aggression, which can interfere with functioning. The purpose of this pilot study is to test whether transdermal nicotine is effective for irritability and/or aggression in adults with ASD using a double-blind, pl...
What is the current status of trial NCT02552147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-09. Estimated completion is 2017-11-17.
What interventions are being tested in trial NCT02552147?
The interventions under investigation include: Transdermal nicotine (DRUG), Transdermal placebo (OTHER).
Who is sponsoring clinical trial NCT02552147?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.